Cancer: antitumor effects of octreotide LAR, a somatostatin analog.
Treatment of nonfunctioning neuroendocrine tumors with somatostatin analogs has been controversial, given the low antitumor effects of these drugs. The ProMid study group now reports that octreotide lar (long-acting release) has a substantial antitumor effect, with longer progression-free survival compared with placebo in patients with well-differentiated neuroendocrine tumors and low tumor burden.